Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring (ADDORA): Multi-centre Open Label Randomised Controlled Trail

NCT04194827 is registered in ClinicalTrials.gov with Reade Rheumatology Research Institute as lead sponsor.

NCT NCT04194827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04194827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring (ADDORA): Multi-centre Open Label Randomised Controlled Trail
Lead sponsor
Reade Rheumatology Research Institute
Phase
Phase 4
Overall status
Unknown status
Start date
March 1, 2020
Completion date
December 31, 2024
Enrollment
267 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis